MedTrace Logo

The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study

NCT06136949 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-11-18

No results posted yet for this study

Summary

This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.

Conditions

Sponsors & Collaborators

  • Centro di Riferimento Oncologico - Aviano

    lead OTHER

Principal Investigators

  • Vincenzo Canzonieri, MD,PhD · Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2032-12-31
Completion
2032-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06136949 on ClinicalTrials.gov